Clinical observation of gemcitabine plus carboplatin in the treatment of elder non-small call lung cancer

Chuan Jin,Lei Ma, Yong-hui Zhang

International Medicine and Health Guidance News(2009)

Cited 0|Views5
No score
Abstract
Objective To evaluate the curative effect and toxicity of Gemcitabine plus Carboplatin in the treatment of elder Non-Small Cell Lung Cancer. Methods sixty five elder Non-Small Cell Lung Cancer were enrolled into this study. Gemcitabine 1000 mg/m2 i. v Results It shows that CR 3.1%, PR 43.1%,NC 32.3%, PD 21.5%. The median time to progress and median survival time was 6.5 and 9.3 months, the one year survival rate was 43.1%. The main side effect include Ⅲ~Ⅳ grade leukopenia 27.7%, Ⅲ grade thombocytopenia 4.6%. Conclu-sion Gemcitabine plus Carboplatin is effective for elder Non-Small Cell Lung Cancer and well tolerated. Key words: Non-Small Cell Lung Cancer; Drug therapy; Combined therapy; Gemcitabine
More
Translated text
Key words
lung cancer,carboplatin,gemcitabine,non-small
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined